Sai Life Sciences (NSE:SAILIFE) EBIT: ₹5,054 Mil (TTM As of Mar. 2026)


NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
18 GF Score
Price ₹1,221.30
! 4 Warning Signs
View Full Analysis

What is Sai Life Sciences EBIT?

Sai Life Sciences NSE:SAILIFE +1.35% 18 EBIT is ₹5,054 Mil as of Mar. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

Sai Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹1,471 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹5,054 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sai Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 was 12.98%. Sai Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sai Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.95%.

Sai Life Sciences  (NSE:SAILIFE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sai Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=5249.64 * ( 1 - 25.13% )/( (0 + 30273.08)/ 1 )
=3930.405468/30273.08
=12.98 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36261.4 - 3369.98 - ( 2618.34 - max(0, 8336.78 - 14105.3+2618.34))
=30273.08

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sai Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=5882.08/( ( (0 + max(0, 0)) + (20791.68 + max(4553.46, 0)) )/ 1 )
=5882.08/( ( 0 + 25345.14 )/ 1 )
=5882.08/25345.14
=23.21 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3736.23 + 1509.68 + 6241.05) - (3369.98 + 0 + 3563.52)
=4553.46

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sai Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=5054.31/259531.091
=1.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences EBIT Related Terms

Sai Life Sciences EBIT Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences EBIT Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
592.66 934.65 1,951.44 3,038.67 5,054.31

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,296.84 931.12 1,214.02 1,438.65 1,470.52

NSE:SAILIFE vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Sai Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sai Life Sciences EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sai Life Sciences's EV-to-EBIT falls into.


NSE:SAILIFE
18GF Score
Sai Life Sciences Ltd NSE:SAILIFE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,054 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹5,054 Mil mean?
Sai Life Sciences (NSE:SAILIFE) has a EBIT of ₹5,054 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sai Life Sciences.
Is Sai Life Sciences' EBIT too high?
Sai Life Sciences' current EBIT is ₹5,054 Mil. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' EBIT compare to TMO and DHR?
Sai Life Sciences' EBIT of ₹5,054 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sai Life Sciences. Sai Life Sciences's current EBIT is ₹5,054 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current EBIT of ₹5,054 Mil. The current EBIT is ₹5,054 Mil. Sai Life Sciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current EBIT is ₹5,054 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score

Get the complete analysis for NSE:SAILIFE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,221.30
Price